AR084620A1 - Una combinacion de un agonista opiaceo y un antagonista opiaceo en el tratamiento de la enfermedad de parkinson - Google Patents

Una combinacion de un agonista opiaceo y un antagonista opiaceo en el tratamiento de la enfermedad de parkinson

Info

Publication number
AR084620A1
AR084620A1 ARP110104969A ARP110104969A AR084620A1 AR 084620 A1 AR084620 A1 AR 084620A1 AR P110104969 A ARP110104969 A AR P110104969A AR P110104969 A ARP110104969 A AR P110104969A AR 084620 A1 AR084620 A1 AR 084620A1
Authority
AR
Argentina
Prior art keywords
dosage form
opiace
parkinson
disease
treatment
Prior art date
Application number
ARP110104969A
Other languages
English (en)
Inventor
Michael Hopp
Claudia Trenkwalder
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43903970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR084620(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of AR084620A1 publication Critical patent/AR084620A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una forma de dosificación farmacéutica que comprende un agonista opiáceo y un antagonista opiáceo para el uso en el tratamiento de la enfermedad de Parkinson. También el uso de un agonista opiáceo y un antagonista opiáceo en esta forma de dosificación.Reivindicación 9: Una forma de dosificación de acuerdo con cualquiera de los ítems 1 a 8, donde la forma de dosificación es una forma de dosificación de liberación prolongada. Reivindicación 11: Una forma de dosificación de acuerdo con el ítem 10, donde la matriz comprende un alcohol graso y un polímero hidrofóbico, preferentemente una alquilcelulosa y más preferentemente etilcelulosa. Reivindicación 13: Una forma de dosificación de acuerdo con cualquiera de los ítems 1 a 12, donde la forma de dosificación es una forma de dosificación oral, preferentemente seleccionada del grupo que comprende un comprimido, una cápsula, un multi-partículas, una gragea, un granulado y un polvo.
ARP110104969A 2010-12-28 2011-12-27 Una combinacion de un agonista opiaceo y un antagonista opiaceo en el tratamiento de la enfermedad de parkinson AR084620A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10197210 2010-12-28

Publications (1)

Publication Number Publication Date
AR084620A1 true AR084620A1 (es) 2013-05-29

Family

ID=43903970

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104969A AR084620A1 (es) 2010-12-28 2011-12-27 Una combinacion de un agonista opiaceo y un antagonista opiaceo en el tratamiento de la enfermedad de parkinson

Country Status (19)

Country Link
US (1) US20140037729A1 (es)
EP (1) EP2658523A1 (es)
JP (2) JP5864606B2 (es)
KR (2) KR101632858B1 (es)
CN (1) CN103347495B (es)
AR (1) AR084620A1 (es)
AU (1) AU2011351447B2 (es)
BR (1) BR112013016862A2 (es)
CA (1) CA2822528C (es)
CL (1) CL2013001943A1 (es)
EA (1) EA025747B1 (es)
MX (1) MX354125B (es)
MY (1) MY162895A (es)
NZ (1) NZ612837A (es)
SG (1) SG191208A1 (es)
TW (2) TW201628618A (es)
UA (1) UA109301C2 (es)
WO (1) WO2012089738A1 (es)
ZA (1) ZA201304303B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011252041B2 (en) 2010-05-10 2014-04-03 Euro-Celtique S.A. Combination of active loaded granules with additional actives
CA2798884C (en) 2010-05-10 2016-09-13 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
TW201628618A (zh) * 2010-12-28 2016-08-16 歐 賽提克股份有限公司 用於治療巴金森氏症的類鴉片激動劑與類鴉片拮抗劑之組合
US10736889B2 (en) 2011-04-29 2020-08-11 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US9918980B2 (en) 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
SI2701707T1 (sl) * 2011-04-29 2021-02-26 Rutgers, The State University Of New Jersey Metoda za zdravljenje diskinezije
US10071088B2 (en) 2012-06-26 2018-09-11 Precondit, Llc Anti-nausea drug combinations
KR20160034352A (ko) * 2013-07-23 2016-03-29 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
EA030310B1 (ru) 2013-11-13 2018-07-31 Эро-Селтик С.А. Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
CA2847781C (en) * 2014-03-28 2019-03-12 Purdue Pharma Reducing drug liking in a subject
US20150352099A1 (en) * 2014-06-04 2015-12-10 Mentinova Inc. Compositions and Methods of Reducing Sedation
WO2016029218A1 (en) 2014-08-22 2016-02-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation
WO2016116615A1 (en) * 2015-01-23 2016-07-28 Euro-Celtique S.A. A combination of hydromorphone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US20160256451A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
CN107660147B (zh) * 2015-05-26 2021-04-30 抗菌技术生物技术研究与发展股份有限公司 用于治疗帕金森病和相关障碍的组合物
US20180104236A1 (en) * 2016-09-26 2018-04-19 Euro-Celtique S. A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
US20230343429A1 (en) * 2019-10-31 2023-10-26 The United States Government As Represented By The Department Of Veterans Affairs Methods, systems, and apparatus for tapering or uptitrating drug dosages

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
EP1299104B1 (en) * 2000-02-08 2009-05-13 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
AU782523B2 (en) * 2000-07-13 2005-08-04 Euro-Celtique S.A. Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics
CA2454328C (en) * 2001-07-18 2008-03-18 Christopher D. Breder Pharmaceutical combinations of oxycodone and naloxone
US20060177381A1 (en) * 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US20070232638A1 (en) * 2006-04-03 2007-10-04 Howard Brooks-Korn Opiopathies
WO2009132313A2 (en) * 2008-04-25 2009-10-29 Progenics Pharmaceuticals, Inc. Morphinan derivatives of organic and inorganic acids
WO2010003963A1 (en) * 2008-07-07 2010-01-14 Euro-Celtique S.A. Use of opioid antagonists for treating urinary retention
JP5886632B2 (ja) * 2009-03-10 2016-03-16 ユーロ−セルティーク エス．エイ． オキシコドンおよびナロキソンを含む即時放出医薬組成物
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
TW201628618A (zh) * 2010-12-28 2016-08-16 歐 賽提克股份有限公司 用於治療巴金森氏症的類鴉片激動劑與類鴉片拮抗劑之組合

Also Published As

Publication number Publication date
CN103347495A (zh) 2013-10-09
MX2013007622A (es) 2013-12-06
ZA201304303B (en) 2014-02-26
CA2822528C (en) 2017-07-18
EP2658523A1 (en) 2013-11-06
JP6074003B2 (ja) 2017-02-01
KR101632858B1 (ko) 2016-06-22
TW201302199A (zh) 2013-01-16
EA201390977A1 (ru) 2013-12-30
CN103347495B (zh) 2017-06-20
NZ612837A (en) 2014-11-28
SG191208A1 (en) 2013-07-31
JP2016040268A (ja) 2016-03-24
JP2014501268A (ja) 2014-01-20
KR20130106431A (ko) 2013-09-27
BR112013016862A2 (pt) 2016-10-04
TW201628618A (zh) 2016-08-16
KR20150076262A (ko) 2015-07-06
EA025747B1 (ru) 2017-01-30
CL2013001943A1 (es) 2013-11-29
US20140037729A1 (en) 2014-02-06
WO2012089738A1 (en) 2012-07-05
CA2822528A1 (en) 2012-07-05
TWI554271B (zh) 2016-10-21
MY162895A (en) 2017-07-31
MX354125B (es) 2018-02-14
JP5864606B2 (ja) 2016-02-17
AU2011351447A1 (en) 2013-07-25
KR101618929B1 (ko) 2016-05-09
AU2011351447B2 (en) 2016-02-25
UA109301C2 (uk) 2015-08-10

Similar Documents

Publication Publication Date Title
AR084620A1 (es) Una combinacion de un agonista opiaceo y un antagonista opiaceo en el tratamiento de la enfermedad de parkinson
ES2409069B2 (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
GB2545368A (en) Diversion-resistant opioid formulations
CR11740A (es) Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
UY35091A (es) Formulaciones de liberacion modificada para oprozomib
MX2012013021A (es) Formulaciones resistentes a alcohol.
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
GT201300304A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
CL2015003596A1 (es) Formulación de liberación modificada
IN2014MN01568A (es)
BR112012018135A2 (pt) preparação farmacêutica, e, método para fabricar a preparação farmacêutica
PE20160520A1 (es) Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion
ES2436344B1 (es) Composición farmacéutica de diacetilmorfina y naloxona para administración oral
ES2502140T1 (es) Comprimidos de liberación inmediata de rasagilina hemitartrato
WO2016193454A3 (en) Dosage of naloxone
WO2013054178A8 (en) Extended release pharmaceutical compositions containing carmabazepine
AR100910A1 (es) Forma de dosificación oral de liberación sostenida que contiene morfina y naloxona
AR089590A1 (es) Sal de bromhidrato de pridopidina
EA201300722A1 (ru) Применение агониста каппа-опиоидных рецепторов периферического действия ici 204,448 для приготовления средств для лечения никотиновой зависимости
TN2013000503A1 (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
TR201005911A2 (tr) Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu.
UA77604U (ru) Производное 1,2,4-триазола, проявляющее актопротекторную активность

Legal Events

Date Code Title Description
FB Suspension of granting procedure